Investor Presentaiton
Novo Nordisk Annual Report 2023
General terms and conditions of 2020-2023 programmes¹
Introducing Novo Nordisk Strategic Aspirations
Risks
Management
Consolidated statements
Additional information.
Employees'
Preliminary number of shares to be allocated 2 (million)
Fair value per restricted stock unit at grant date (DKK)
Performance and vesting period
Allocation date
Amortisation period
100 year
anniversary
programme
2023
2023
Management Board
2022
Management group below Management Board
Individual employees
2021
2020
2023
2022
2021
2020
2023
2022
2021
3.0
0.6
0.7
1.0
0.9
3.1
3.3
3.0
2.4
0.3
0.8
0.3
446
2023 to 2026
Aug 2026
3.5 years
456
320
2022 to 2024 2021 to 2023 2020 to 2023
Feb 2025 Feb 2024
Feb 2024
3 years
3 years
4 years
212
206
456
2023 to 2025
Feb 2026
3 years
320
212
2022 to 2024 2021 to 2023 2020 to 2023
Feb 2025 Feb 2024 Feb 2024
3 years
4 years
206
3 years
544
2023 to 2026
2026
3 years
371
2022 to 2025 2021 to 2024
2025
269
2024
3 years
3 years
2023 to 2025
Feb 2026
3 years
1. As of 13 September 2023, the trading unit of the Novo Nordisk B shares listed on NASDAQ Copenhagen and ADRs listed on the New York Stock Exchange (NYSE) was changed from DKK 0.20 to DKK 0.10. Comparative figures have been restated to reflect the change in trading unit from DKK 0.20 to DKK 0.10. 2. The number of shares to be allocated
under the LTIPS to Management Board and management group below Management Board, respectively, may potentially be reduced or increased depending on whether Novo Nordisk's performance during the three-year performance period is higher or lower compared to targets determined by the Board. The maximum number is capped.
77View entire presentation